These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 26364504)
41. Clinical translation of a PSMA inhibitor for Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503 [TBL] [Abstract][Full Text] [Related]
42. Introduction of an 8-aminooctanoic acid linker enhances uptake of 99mTc-labeled lactam bridge-cyclized α-MSH peptide in melanoma. Guo H; Miao Y J Nucl Med; 2014 Dec; 55(12):2057-63. PubMed ID: 25453052 [TBL] [Abstract][Full Text] [Related]
43. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166 [TBL] [Abstract][Full Text] [Related]
44. Oxidation of methionine - is it limiting the diagnostic properties of 99mTc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist? Janota B; Karczmarczyk U; Laszuk E; Garnuszek P; Mikołajczak R Nucl Med Rev Cent East Eur; 2016; 19(2):104-10. PubMed ID: 27479787 [TBL] [Abstract][Full Text] [Related]
45. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797 [TBL] [Abstract][Full Text] [Related]
46. [ Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071 [TBL] [Abstract][Full Text] [Related]
47. In vitro evaluation of (99m)Tc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell lines. Yurt Lambrecht F; Durkan K; Ozgür A; Gündüz C; Avcı CB; Susluer SY J Drug Target; 2013 May; 21(4):383-8. PubMed ID: 23301856 [TBL] [Abstract][Full Text] [Related]
48. Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide. Karczmarczyk U; Garnuszek P; Maurin M; Di Gialleonardo V; Galli F; Signore A; Mikołajczak R Nucl Med Biol; 2010 Oct; 37(7):795-803. PubMed ID: 20870154 [TBL] [Abstract][Full Text] [Related]
50. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical. Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305 [TBL] [Abstract][Full Text] [Related]
51. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Faintuch BL; Teodoro R; Duatti A; Muramoto E; Faintuch S; Smith CJ Nucl Med Biol; 2008 May; 35(4):401-11. PubMed ID: 18482677 [TBL] [Abstract][Full Text] [Related]
53. Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy. De K; Bhowmik A; Behera A; Banerjee I; Ghosh MK; Misra M J Pept Sci; 2012 Dec; 18(12):720-30. PubMed ID: 23109400 [TBL] [Abstract][Full Text] [Related]
54. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963 [TBL] [Abstract][Full Text] [Related]
55. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic? Wild D; Antwi K; Fani M; Christ ER J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073 [TBL] [Abstract][Full Text] [Related]
56. Studies on batch formulation of a kit for the preparation of the 99mTc-Ubiquicidin (29-41): An infection imaging agent. Arjun C; Mukherjee A; Bhatt J; Chaudhari P; Repaka KM; Venkatesh M; Samuel G Appl Radiat Isot; 2016 Jan; 107():8-12. PubMed ID: 26405838 [TBL] [Abstract][Full Text] [Related]
57. Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits. González-Vázquez A; Ferro-Flores G; Arteaga de Murphy C; Gutiérrez-García Z Appl Radiat Isot; 2006 Jul; 64(7):792-7. PubMed ID: 16542847 [TBL] [Abstract][Full Text] [Related]
58. Innovative imaging of insulinoma: the end of sampling? A review. Christ E; Antwi K; Fani M; Wild D Endocr Relat Cancer; 2020 Apr; 27(4):R79-R92. PubMed ID: 31951592 [TBL] [Abstract][Full Text] [Related]
59. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors. Parisella MG; Chianelli M; D'Alessandria C; Todino V; Mikolajczak R; Papini E; Dierckx RA; Scopinaro F; Signore A Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):90-8. PubMed ID: 21068709 [TBL] [Abstract][Full Text] [Related]
60. Preparation and evaluation of Maleki F; Masteri Farahani A; Sadeghzadeh N; Mardanshahi A; Abediankenari S Chem Biol Drug Des; 2020 Nov; 96(5):1223-1231. PubMed ID: 32426902 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]